Clinical Research in Cardiology最新文献

{"title":"Comparison of iron deficiency markers in patients with advanced heart failure.","authors":"Maria Bakosova, Jan Krejci, Julius Godava, Eva Ozabalova, Hana Poloczkova, Tomas Honek, Peter Hude, Jan Machal, Helena Bedanova, Petr Nemec","doi":"10.1007/s00392-025-02775-5","DOIUrl":"10.1007/s00392-025-02775-5","url":null,"abstract":"<p><strong>Introduction: </strong>Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF). It is associated with reduced performance, frequent hospitalizations and low quality of life. There is an ongoing debate about the correct definition of ID in HF.</p><p><strong>Purpose: </strong>Refinement of the ID determination in patients with advanced HF. Evaluation of the association of iron metabolism parameters with other clinical characteristics.</p><p><strong>Patients and methods: </strong>One hundred-two patients with advanced HF were included, 48 in-patients, out-patients without LVAD and 25 of patients with LVAD implanted. In addition to conventional tests, we monitored iron metabolism parameters. The prevalence of ID was compared according to both the original and the updated ID definition. Correlations between individual iron markers and patients' functional capacity were measured.</p><p><strong>Results: </strong>The prevalence of ID in patients with advanced HF was 65%. There was no statistically significant difference in individual iron parameters between the groups. All parameters except ferritin correlated with NT-proBNP in the in-patient group. Serum iron correlated most strongly with NT-proBNP and CRP across all groups. The sTfR parameter correlated the most with right heart catheterization parameters, serum iron and TSAT were the most specific parameters related to functional status.</p><p><strong>Conclusion: </strong>Patients with more advanced HF and severe limitation of functional capacity had worse iron parameters. Ferritin seems to be the less specific marker of ID, while detecting ID using serum iron and TSAT seems to be reliable. The correlation of ferritin with functional status or haemodynamics was the weakest of all the parameters studied.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1559-1570"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular dysfunction and heart failure with preserved ejection fraction.","authors":"Ornela Velollari, Antonio Biancofiore, Maximilian Olschewski, Helen Ullrich-Daub, Thomas Münzel, Karl-Philipp Rommel, Philipp Lurz, Tommaso Gori, Karl-Patrik Kresoja","doi":"10.1007/s00392-025-02822-1","DOIUrl":"10.1007/s00392-025-02822-1","url":null,"abstract":"<p><strong>Background and aim: </strong>The impact of coronary microvascular dysfunction (CMD) on parameters of systolic and diastolic function, particularly in patients with heart failure and preserved ejection fraction (HFpEF), is poorly understood. Although these conditions often overlap, their combined impact on parameters of systolic and diastolic function remains unexplored.</p><p><strong>Methods: </strong>Consecutive patients undergoing invasive CMD assessment were enrolled. Systolic function was assessed by global longitudinal strain (GLS), diastolic function by E/E', left atrial reservoir strain (LARS), and non-invasive single-beat pressure-volume relationship stiffness constant (β) estimation.</p><p><strong>Results: </strong>Of 145 patients, 72 (49.7%) had CMD, 35 (24%) HFpEF, and 23 (16%) both conditions. HFpEF was twice as prevalent in CMD patients as compared to patients without CMD (32% vs. 16%, p = 0.034). Both CMD was associated with parameters of both diastolic (E/E' β = 0.29, p < 0.001, LV stiffness constant β = 0.23; p = 0.006, and LARS β = -0.21, p = 0.02) and systolic function (GLS β = 0.31, p < 0.001). The presence of CMD was associated with an impairment in LV stiffness both in patients with and without HFpEF (p for interaction = 0.044).</p><p><strong>Conclusion: </strong>HFpEF is highly prevalent in patients with CMD, and CMD is associated with both systolic and diastolic dysfunction. In patients with HFpEF, an additional worsening of diastolic function is observed.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1592-1602"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145932577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving trends and persistent challenges in chronic left ventricular heart failure management: insights from a 9-year analysis of in-hospital outcomes in Germany.","authors":"Anastasia Janina Hobbach, Jannik Feld, Jürgen Reinhard Sindermann, Holger Reinecke","doi":"10.1007/s00392-025-02679-4","DOIUrl":"10.1007/s00392-025-02679-4","url":null,"abstract":"<p><strong>Aims: </strong>Chronic left ventricular heart failure (CLHF) represents a significant public health challenge globally, marked by high morbidity and mortality. CLHF is a leading cause of hospitalization, placing considerable strain on healthcare systems. This study aims to analyze in-hospital outcomes for CLHF patients in Germany over nine years (2014-2022), examining trends in morbidity, mortality, healthcare costs, and complications.</p><p><strong>Methods and results: </strong>Data were sourced from the Federal Statistical Office (DESTATIS), covering 2,616,462 inpatient CLHF cases (ICD-10-GM I50.11-I50.14) in Germany from 2014 to 2022. CLHF hospitalizations increased from 288,019 in 2014 to 311,782 in 2019, then declined in 2020 but started again to rise from 2021 to 2022. The proportion of patients with advanced CLHF (NYHA stage IV) decreased slightly from 54.09% in 2014 to 50.36% in 2020 (p < 0.0001). Notable comorbidity trends included rising rates of atrial fibrillation and chronic kidney disease. Complications such as cardiogenic shock and acute kidney injury increased over time (both p < 0.0001). Despite a decrease in mortality rates from 2014 to 2019 (p < 0.0001), in-hospital mortality rose to 8.84% in 2022 (p < 0.0001). Median revenue volume and hospitalization duration showed a pre-pandemic increase but declined in 2020.</p><p><strong>Conclusion: </strong>The study highlights a complex interplay of factors affecting CLHF management in Germany, as a representative example for a high-income country. While advancements in treatment have improved some outcomes, the COVID-19 pandemic significantly impacted hospitalization trends and in-hospital mortality. The findings underscore the need for ongoing improvements in CLHF management and resilient healthcare strategies to address future challenges.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1522-1532"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ADA-HF: acetazolamide as a chloride sparing diuretic in patients admitted to hospital with heart failure.","authors":"J J Cuthbert, E Luo, A S M Ahmed, M Ajith, H Butt, H Pinhol, F Baffour Korsah, J Bulemfu, S Ford, G Constable, L Cox, A S Rigby, A L Clark","doi":"10.1007/s00392-026-02915-5","DOIUrl":"10.1007/s00392-026-02915-5","url":null,"abstract":"<p><strong>Background: </strong>We assessed whether oral acetazolamide (ACZ) increases diuresis and reduces chloride loss when given alongside high-dose intravenous (IV) furosemide in patients admitted to hospital with HF.</p><p><strong>Methods and results: </strong>ADA-HF was a single-centre, open-label, randomised controlled trial. Patients were randomised to ACZ 250 mg twice daily plus high-dose (240 mg per day) IV furosemide infusion (standard of care (SoC)) versus SoC alone for 4 days. The co-primary endpoints were (1) daily net fluid loss between baseline and day 4 and (2) change in serum chloride level from baseline to day 4. A total of 46 patients (median age, 76; 65% male; median N-terminal pro-B-type natriuretic peptide, 4097 ng/L) from a screened population of 207 were randomised (23 to ACZ, 23 to SoC). The median daily net fluid loss was 1073 mL (1st-3rd quartile range 682-1419 mL) in the ACZ arm vs. 1029 mL (201-1432 mL) in the SoC arm (P = 0.51). There was no change in serum chloride concentration in the ACZ arm, whereas chloride fell by 7 (2-10) mmol/L in the SoC arm (P < 0.001). The number of adverse and serious adverse events ((S)AE) was numerically greater in the ACZ arm (51 events in 16 patients vs. 29 events in 10 patients, P = 0.24). Overall, 8 patients (30%) experienced (S)AEs possibly related to ACZ, and two of whom withdrew from the trial.</p><p><strong>Conclusions: </strong>Acetazolamide has a significant \"chloride-sparing\" effect in patients given high-dose IV furosemide. However, ACZ did not significantly increase diuresis, and side effects from oral ACZ were frequent.</p><p><strong>Trial registration: </strong>ISRCTN13060336; 9/2/2023.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1675-1685"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study.","authors":"Luisa Ojeda-Fernández, Ginevra Torrigiani, Mauro Molteni, Ida Fortino, Claudio Cimminiello, Marta Baviera","doi":"10.1007/s00392-025-02674-9","DOIUrl":"10.1007/s00392-025-02674-9","url":null,"abstract":"<p><strong>Objective: </strong>Evidence on the impact of GLP-1 RAs on HF hospitalization (HHF) and mortality has been inconsistent across clinical trials in patients with diabetes. We investigated the association between GLP-1 RAs and these outcomes in a real-world setting.</p><p><strong>Methods: </strong>We selected individuals aged 45 years and older already treated with metformin living in Lombardy, Italy, and then split them into two groups if they initiated GLP-1 RAs or other antidiabetic drugs, between 2019 and 2021. A multivariable Cox proportional hazard regression model was performed to assess the association of GLP-1 RAs on HHF and all-cause death as hazard ratios (HRs) with 95% CI compared to the Other ADs group, stratifying by history of HF. The role of GLP-1 RAs was also investigated using the Inverse Probability Treatment Weighting (IPTW) and in the subgroup analyses.</p><p><strong>Results: </strong>In total, 9795 patients in the GLP-1 RAs group (302 with HF; 9493 without) and 6018 in the Other ADs group (405 with HF; 5613 without) were included in the analysis. GLP-1 RAs use was significantly associated with a lower risk of HHF in patients with a history of HF (HR 0.65; CI 95% 0.426-0.987) and in those without (HR 0.52; CI 95% 0.371-0.733). A lower risk for all-cause death was also observed in GLP-1 RAs users (with HF: HR 0.45; CI 95% 0.320-0.638; without HF: HR 0.44; CI 95% 0.383-0.514). The results of the IPTW and subgroup analyses confirmed those of the main analysis.</p><p><strong>Conclusion: </strong>Our findings showed a benefit of GLP-1 RAs on HHF and all-cause death in patients with diabetes regardless of HF history. Although, our study presents several limitations, if confirmed through dedicated randomized trial, this could further expand the role of GLP-1RAs in cardiovascular prevention\".</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1512-1521"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in clinical features and 1-year outcomes of patients with heart failure and reduced, mildly reduced, and preserved ejection fraction in a contemporary cohort: is the clinical profile changing?","authors":"María Anguita-Gámez, Juan L Bonilla-Palomas, Alejandro Recio-Mayoral, Rafael González-Manzanares, Javier Muñiz-García, Nieves Romero-Rodríguez, Francisco J Elola-Somoza, Angel Cequier-Fillat, Luis Rodríguez-Padial, Manuel Anguita-Sánchez","doi":"10.1007/s00392-025-02632-5","DOIUrl":"10.1007/s00392-025-02632-5","url":null,"abstract":"<p><strong>Aims: </strong>To analyze in a contemporary registry of heart failure (HF) patients followed in specialized HF units in Spain, the differences in clinical features, treatment, and 1-year outcomes in HF with reduced, mildly reduced, and preserved left ventricular ejection fraction.</p><p><strong>Methods and results: </strong>We analyzed data from the registry of the SEC-Excelente-IC quality accreditation program of the Spanish Society of Cardiology, with 1716 patients with HF included between 2019 and 2021 by 45 specialized HF units accredited by the SEC. Treatment and 1-year mortality, HF hospitalizations and decompensations of HF used were compared according to the type of HF. Of the 1,716 patients, 55.5% had HFrEF, 11.9% had HFmrEF, and 32.6% had HFpEF. HFpEF patients were older and had a higher proportion of women, atrial fibrillation, and hypertension. Sacubitril-valsartan and mineral receptor antagonists were used in greater proportion in HFrEF (56.5% and 73%, respectively, p < 0.001), but also in 10.3 and 33% in HFpEF. One-year mortality (17.3 vs 20.9 vs 15.6/100 persons-year; p = 0.321), 1-year HF hospitalizations (34.4 vs 29.5 vs 26.7/100 persons-year; p = 0.330), and 1-year decompensations of HF without hospitalization (13.1 vs 10.4 vs 11.1; p = 0.393) were similar for the 3 types of HF.</p><p><strong>Conclusion: </strong>In our contemporary cohort of real-life HF patients, slight differences were observed in clinical features and treatment between the 3 types of HF, but the prevalence of most of the major comorbidities and 1-year outcomes (mortality, hospitalizations and decompensations of HF) were similar in the 3 groups.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1486-1497"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early palliative care in heart failure shows neutral effects across EF subtypes: an exploratory EPCHF secondary analysis.","authors":"Mahmoud Balata, Asim Khan, Marwa Hassan, Islam Ebeid, Jasmin Ortak, Hüseyin Ince, Marc Ulrich Becher","doi":"10.1007/s00392-025-02828-9","DOIUrl":"10.1007/s00392-025-02828-9","url":null,"abstract":"<p><strong>Introduction: </strong>Early integration of palliative care (EIPC) has been proposed to improve quality of life in heart failure (HF), but evidence is mixed and potential differences by HF subtype remain unclear. This exploratory secondary analysis of the EPCHF trial examined whether patient-reported outcomes differed between patients with and without reduced EF.</p><p><strong>Methods: </strong>A total of 205 patients with symptomatic HF were randomized 1:1 to EIPC or standard care in the EPCHF trial. For this exploratory analysis, patients were stratified by left ventricular ejection fraction (≤ 40% vs > 40%). Patient-reported outcomes were assessed over 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ), Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-PAL), Hospital Anxiety and Depression Scale (HADS), MIDOS, and FACIT-SP12.</p><p><strong>Results: </strong>KCCQ scores, HADS-anxiety, and MIDOS symptom intensity improved significantly over 12 months in both EIPC and control groups, with no significant between-group differences in either EF subgroup. Reductions in HADS-depression occurred only in patients with HFrEF, with similar improvements in both EIPC (-1.37; 95% CI: -2.31 to -0.44; p = 0.004) and control (-1.99; 95% CI: -2.89 to -1.09; p < 0.001). Among patients with LVEF > 40%, EIPC produced a significant improvement in spiritual well-being compared with standard care (mean difference 3.47; 95% CI: 0.32 to 6.62; p = 0.031), whereas the control group showed no improvement. Mortality and hospitalization rates did not differ between groups.</p><p><strong>Conclusion: </strong>In this exploratory EF-stratified analysis of EPCHF trial, EIPC did not improve overall HRQOL, mood, or symptom burden compared with standard care. A significant effect was observed only for spiritual well-being in patients with LVEF > 40%, suggesting that this subgroup may have distinct supportive-care needs warranting further investigation.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1603-1614"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HI-PLUS: design of a cluster-randomized trial evaluating structured case management with telemonitoring to improve quality of life in heart failure.","authors":"Martha Schutzmeier, Viktoria Rücker, Jonas Widmann, Peer Papior, Lisa Kimmelmann, Fabian Kerwagen, Lorenz Heil, Helena Manger, Andrea Szczesny, Yannick Maaser, Bettina Zippel-Schultz, Thomas Helms, Peter U Heuschmann, Stefan Störk","doi":"10.1007/s00392-026-02904-8","DOIUrl":"10.1007/s00392-026-02904-8","url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure (HF) remains a leading cause of hospitalization and death in Germany, significantly impairing patients' quality of life (QoL) despite advances in therapy. Structured, multidisciplinary care programs may improve long-term outcomes. HI-PLUS is a pragmatic trial investigating whether a complex intervention can improve QoL in HF patients. We describe the trial design and pilot feasibility study findings.</p><p><strong>Methods and results: </strong>HI-PLUS is a cluster-randomized, parallel-arm controlled trial (DRKS00031997) targeting 56 clusters, each comprising a cardiology practice and up to five general practitioners (GPs), targeting 1350 patients. The control arm receives guideline-recommended care. The intervention adds five elements: (a) care supported by specially trained non-physician staff HF qualified (HF-MPA); (b) accredited HF-MPA training curriculum certified by the German Society of Cardiology; (c) eHealth platform for telemonitoring and symptom reporting; (d) portable telemedical devices, if needed; and (e) enhanced communication between cardiologists and GPs facilitated by HF-MPAs and the eHealth platform. The primary endpoint is change in HF-specific QoL after 12 months, measured by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS). A pilot feasibility study that was conducted prior to commencement of patient recruitment confirmed the feasibility and acceptability of the proposed trial procedures.</p><p><strong>Conclusion: </strong>The HI-PLUS trial addresses recognized gaps in HF care. If effective, it could serve as a scalable model for integrated HF care throughout Germany.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1664-1674"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of fully-automated AI based CT-analysis on pre-procedural TAVI planning.","authors":"Mani Arsalan, Tami Duske, Hanna Schneider, Alexander R Tamm, Philipp Christian Seppelt, Martin Geyer, Kerstin Piayda, Ralph Stephan von Bardeleben, Simon Martin, David Leistner, Michaela Hell, Thomas Walther, Felix Kreidel","doi":"10.1007/s00392-026-03017-y","DOIUrl":"https://doi.org/10.1007/s00392-026-03017-y","url":null,"abstract":"<p><strong>Background: </strong>Accurate pre-procedural computed tomography (CT) analysis is essential for optimal valve sizing and clinical outcomes in transcatheter aortic valve implantation (TAVI). Recently, fully automated, artificial intelligence (AI)-based CT analysis platforms have been developed to simplify and standardize this process.</p><p><strong>Aims: </strong>The aim of the study was to investigate the clinical impact of this new analysis method on the selection of valve prosthesis size.</p><p><strong>Methods: </strong>Overall, 247 patients with symptomatic severe aortic stenosis were enrolled. Patients underwent TAVI procedures at two different heart centres. The pre-procedural datasets were analysed by a standard TAVI CT-analysis software (3M, Pie Medical Imaging BV, The Netherlands) and a fully-automated CT-analysis-platform employing a deep-learning based algorithm. Key annular measurements and simulated prosthesis size selection were compared between both methods.</p><p><strong>Results: </strong>The mean aortic annulus diameter was 24.5 ± 2.3 mm (3mensio) and 24.4 ± 2.4 mm (AI), respectively, with a mean absolute error (MAE) of 0.6 mm and mean absolute percentage error (MAPE) of 2.6%. Annulus perimeter (76.9 ± 7.0 mm vs. 74.6 ± 7.3 mm; MAE: 2.0 mm; MAPE: 2.6%) and annulus area (458.4 ± 87.2 mm² vs. 440.9 ± 85.6 mm²; MAE: 21.2 mm²; MAPE: 4.6%) showed excellent correlation (intraclass correlation coefficients > 0.95). Prosthesis size selection simulated on the basis of AI-derived measurements would have differed from the implanted size in 21% of patients, compared with 14% when using the semi-automated method.</p><p><strong>Conclusions: </strong>In this retrospective study, fully automated AI-based CT analysis demonstrated excellent agreement with conventional semi-automated measurements of the aortic annulus. Nevertheless, similar to established planning workflows, expert interpretation remains crucial to integrate the broader anatomical and clinical context required for optimal prosthesis size selection.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148873406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis.","authors":"Mahmoud Balata, Atsushi Sugiura, Marwa Hassan, Mohamed Rady, Marian Christoph, Karim Ibrahim, Marc Ulrich Becher, Akram Youssef","doi":"10.1007/s00392-025-02694-5","DOIUrl":"10.1007/s00392-025-02694-5","url":null,"abstract":"<p><strong>Background and objective: </strong>Obesity is common in heart failure (HF), worsening quality of life and depressive symptoms. While semaglutide, a GLP-1 agonist, aids weight loss in obese adults, its impact on health and mood in obese HF patients is unclear. This study evaluated semaglutide's effects on body weight, health status, and mood in obese HF patients over one year.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 122 obese HF patients treated consecutively with semaglutide between January 2019 and August 2023. The primary endpoints were changes in body mass index (BMI), Hospital Anxiety and Depression Scale (HADS) scores, and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS) from baseline to one year. Secondary endpoints included changes in NYHA functional class and NT-proBNP levels.</p><p><strong>Results: </strong>Semaglutide treatment resulted in a significant weight reduction at one year, with a mean BMI decrease of -2.23 kg/m² (95% CI -2.71 to -1.75; p < 0.001). This weight reduction was consistent across patients with baseline BMI < 35 kg/m² and ≥ 35 kg/m² (p for interaction = 0.26). HADS anxiety scores decreased from a baseline of 5 points (IQR: 2-8) to 3 points (IQR: 1-7; p = 0.037), while HADS depression scores decreased from 6 points (IQR: 3-8) to 3 points (IQR: 1-6; p < 0.001). KCCQ-OSS scores improved from 62 points (IQR: 52-77) at baseline to 82 points (IQR: 55-95; p < 0.001) at one year. These improvements in HADS depression and KCCQ-OSS scores were consistent across all subgroups, including those with baseline LVEF (≥ 50% or < 50%), BMI (≥ 35 kg/m² or < 35 kg/m²), ischemic versus non-ischemic cardiomyopathy, and the presence or absence of diabetes. Additionally, significant improvements in NYHA class and NT-proBNP levels were observed at one year.</p><p><strong>Conclusion: </strong>Semaglutide significantly improves health status and mood in obese heart failure patients, with these improvements strongly correlating with weight loss.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1533-1542"},"PeriodicalIF":3.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}